Target intelligence / Profile preview

RNA polymerase enzyme (RNAP or RNA Pol)

Target
RNAP or RNA Pol
Molecular classification
Enzyme, Transcription factor (functional), Other: multi-subunit enzyme complex
01

Overview

RNA polymerase enzyme is a multi-subunit enzyme complex responsible for synthesizing RNA from a DNA template, a process called transcription[1][2][4][5][6][7]. Found in all living organisms and many viruses, it is essential for the first step in gene expression. In bacteria, a single RNA polymerase synthesizes all types of RNA, whereas in eukaryotes, multiple specialized forms exist: RNA polymerase I (rRNA synthesis), II (mRNA and some non-coding RNAs), and III (tRNA and small RNAs)[2][5][6]. The core enzyme typically consists of five subunits (α2, β, β′, ω) and, in bacteria, associates with a sixth, the sigma (σ) factor, to form the holoenzyme for initiation specificity[1][2][4][6]. RNA polymerase is a validated therapeutic target for antibiotics (e.g., rifampicin), and its dysfunction or inhibition underlies the mechanisms of some anticancer agents and toxins[5]. Specificity and essentiality make it a key molecular target for both research and therapy, while resistance or off-target effects remain significant concerns[5].

Other names
DNA-directed RNA polymeraseRNAPRNA PolRNA polymerase IRNA polymerase IIRNA polymerase III (for eukaryotic subtypes)DNA-dependent RNA polymerase
02

Mechanism of action

Inhibition of RNA chain initiation by blocking RNAP binding (e.g., rifampicin) - Inhibition of RNA chain elongation (e.g., α-amanitin) - Blocking active site or DNA binding (e.g., actinomycin D)

03

Biological functions

Transcription (synthesis of RNA from a DNA template)Gene expression regulationRNA processing (by generating non-coding RNAs such as tRNA, rRNA, miRNA)
04

Disease associations

Infection (therapeutic target in antibacterial and antiviral therapy)Cancer (targeted in transcriptional dysregulation)Other (drug resistance in pathogens, toxin biosynthesis)
05

Safety considerations

Off-target inhibition can disrupt essential gene expression in host cellsCytotoxicity, particularly for drugs or toxins that affect human RNA polymerasesRisk of resistance when RNAP is targeted in pathogens
06

Interacting drugs

Rifampicin (antibacterial)

5 more in the full profile.

07

Biomarkers

rpoB mutations in pathogens (rifampicin resistance marker)RNAP II levels or phosphorylation status (biomarker for cellular proliferation or response to therapy)

Beyond the preview

Go deeper on RNA polymerase enzyme (RNAP or RNA Pol).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA polymerase enzyme (RNAP or RNA Pol).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call